Randomized trial · people
Exenatide plus dapagliflozin: UACR fell 39.6% vs 11.0% on placebo
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, exenatide alone did not clearly change kidney markers over 16 weeks. Pairing it with dapagliflozin showed a larger drop in urine albumin from baseline, but that drop was not statistically significant against placebo.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 66
- Published
- 2021
- Journal
- Diabetes Obes Metab
What they tested
The team tested whether exenatide twice daily, the diabetes drug dapagliflozin, or both together change markers of kidney function in obese people with type 2 diabetes.
How the study was done
This was a planned secondary analysis of a 16-week randomized, double-blind, placebo-controlled trial in 66 obese people with type 2 diabetes. Groups got exenatide, dapagliflozin, both, or placebo (a dummy treatment).

What they found
At week 16, UACR (the albumin-to-creatinine ratio in 24-hour urine) changed from baseline by -39.6% with the combination (P = 0.001), -18.1% with dapagliflozin, -15.6% with exenatide alone and -11.0% with placebo, and only the combination's change was statistically significant. Against placebo, the combination's UACR difference was -32.2% (P = 0.159), which was not statistically significant. The combination brought an early dip in estimated GFR, a measure of kidney filtering, of -10.4 mL/min/1.73 m2 by cystatin C (P < 0.001) and -4.0 mL/min/1.73 m2 by creatinine (P = 0.129), compared with placebo. Kidney injury molecule-1 relative to creatinine was 43.8% lower with the combination than with placebo (P = 0.129).
What it doesn’t show
This was a small, 16-week secondary analysis that tracked lab markers, not kidney disease outcomes. The combination's edge over placebo on UACR was not statistically significant, so the authors' view that the two drugs work together is tentative.
The paper
van Ruiten et al. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial. Diabetes Obes Metab. 2021.
The compound
More studies on Exenatide
- Exenatide: no cognitive benefit in mild cognitive impairmentRandomized trial · people · 2024
- Exenatide: lower intracranial pressure in IIH over 12 weeksRandomized trial · people · 2023
- Exenatide did not cut heavy drinking days in alcohol use disorderRandomized trial · people · 2022
- Exenatide: 29.2% spontaneous pregnancy vs 14.7% on metformin in PCOSRandomized trial · people · 2022
- Exenatide, alone or with dapagliflozin, improved blood sugar in PCOSRandomized trial · people · 2021
- Exenatide ER: 0.9% HbA1c drop vs 1.5% with semaglutide in SUSTAIN 3Randomized trial · people · 2018
- Every study on Exenatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.